Jianhan Huang1, Meijun Zheng2, Zongliang Zhang3, Xin Tang1, Yaxing Chen1, Aijun Peng1, Xingchen Peng3, Aiping Tong4, Liangxue Zhou5. 1. Department of Neurosurgery, West China Hospital, West China Medical School, Sichuan University, No. 37 Guo Xue Xiang, Chengdu, 610041, Sichuan Province, People's Republic of China. 2. Department of Otolaryngology, Head and Neck Surgery, West China Hospital, West China Medical School, Sichuan University, No. 37 Guo Xue Xiang, Chengdu, 610041, Sichuan Province, People's Republic of China. 3. State Key Laboratory of Biotherapy, West China Hospital, West China Medical School, Sichuan University, No. 37 Guo Xue Xiang, Chengdu, 610041, Sichuan Province, People's Republic of China. 4. State Key Laboratory of Biotherapy, West China Hospital, West China Medical School, Sichuan University, No. 37 Guo Xue Xiang, Chengdu, 610041, Sichuan Province, People's Republic of China. aipingtong@scu.edu.cn. 5. Department of Neurosurgery, West China Hospital, West China Medical School, Sichuan University, No. 37 Guo Xue Xiang, Chengdu, 610041, Sichuan Province, People's Republic of China. liangxue_zhou@126.com.
Abstract
BACKGROUND: T cell with chimeric antigen receptors (CAR-T) has presented remarkable efficacy for blood cancer as an emerging immunotherapy. However, for solid tumors, the therapeutic efficacy is much impaired due to the lack of infiltration and persistence of CAR-T in tumor tissue. Thus, we constructed an interleukin-7-loaded oncolytic adenovirus and combined the use of oncolytic virus and CAR-T to improve the therapeutic outcome. METHODS: We constructed an interleukin-7-loaded oncolytic adenovirus (oAD-IL7) and a B7H3-targeted CAR-T and explored the efficacy of the single use of oAD-IL7, B7H3-CAR-T, or the combined therapy for glioblastoma in vitro and in vivo. The improved CAR-T anti-tumor efficacy was evaluated according to the proliferation, survival, persistence, exhaustion of T cells, and tumor regression. RESULTS: Constructed oAD-IL7 and B7H3-CAR-T presented moderate cytotoxicity during in vitro study, but failed to induce a thorough and persistent anti-tumor therapeutic efficacy in vivo. The combination of oAD-IL7 and B7H3-CAR-T in vitro resulted in enhanced T cell proliferation and reduced T cell apoptosis. The joint efficacy was further confirmed using tumor-bearing xenograft mice. During in vivo study, the mice treated with both oAD-IL7 and B7H3-CAR-T showed prolonged survival and reduced tumor burden. According to the ex vivo study, oAD-IL7 improved the proliferation and persistence of tumor-infiltrating B7H3-CAR-T, but failed to reverse the exhaustion. CONCLUSIONS: Our results indicated that oAD-IL7 is a promising auxiliary therapy to improve the therapeutic efficacy of B7H3-CAR-T in glioblastoma by providing the activating signals for tumor-infiltrating T cells. Our results also lay the basis for the future clinical trials for the combination of IL7-loaded oncolytic adenovirus and CAR-T therapy for glioblastoma.
BACKGROUND: T cell with chimeric antigen receptors (CAR-T) has presented remarkable efficacy for blood cancer as an emerging immunotherapy. However, for solid tumors, the therapeutic efficacy is much impaired due to the lack of infiltration and persistence of CAR-T in tumor tissue. Thus, we constructed an interleukin-7-loaded oncolytic adenovirus and combined the use of oncolytic virus and CAR-T to improve the therapeutic outcome. METHODS: We constructed an interleukin-7-loaded oncolytic adenovirus (oAD-IL7) and a B7H3-targeted CAR-T and explored the efficacy of the single use of oAD-IL7, B7H3-CAR-T, or the combined therapy for glioblastoma in vitro and in vivo. The improved CAR-T anti-tumor efficacy was evaluated according to the proliferation, survival, persistence, exhaustion of T cells, and tumor regression. RESULTS: Constructed oAD-IL7 and B7H3-CAR-T presented moderate cytotoxicity during in vitro study, but failed to induce a thorough and persistent anti-tumor therapeutic efficacy in vivo. The combination of oAD-IL7 and B7H3-CAR-T in vitro resulted in enhanced T cell proliferation and reduced T cell apoptosis. The joint efficacy was further confirmed using tumor-bearing xenograft mice. During in vivo study, the mice treated with both oAD-IL7 and B7H3-CAR-T showed prolonged survival and reduced tumor burden. According to the ex vivo study, oAD-IL7 improved the proliferation and persistence of tumor-infiltrating B7H3-CAR-T, but failed to reverse the exhaustion. CONCLUSIONS: Our results indicated that oAD-IL7 is a promising auxiliary therapy to improve the therapeutic efficacy of B7H3-CAR-T in glioblastoma by providing the activating signals for tumor-infiltrating T cells. Our results also lay the basis for the future clinical trials for the combination of IL7-loaded oncolytic adenovirus and CAR-T therapy for glioblastoma.
Authors: Mahiuddin Ahmed; Ming Cheng; Qi Zhao; Yehuda Goldgur; Sarah M Cheal; Hong-fen Guo; Steven M Larson; Nai-kong V Cheung Journal: J Biol Chem Date: 2015-10-20 Impact factor: 5.157
Authors: Tatiana V Kudling; James H A Clubb; Dafne C A Quixabeira; Joao M Santos; Riikka Havunen; Alexander Kononov; Camilla Heiniö; Victor Cervera-Carrascon; Santeri Pakola; Saru Basnet; Susanna Grönberg-Vähä-Koskela; Victor Arias; Ivan Gladwyn-Ng; Katri Aro; Leif Bäck; Jari Räsänen; Ilkka Ilonen; Kristian Borenius; Mikko Räsänen; Otto Hemminki; Antti Rannikko; Anna Kanerva; Johanna Tapper; Akseli Hemminki Journal: Oncoimmunology Date: 2022-07-12 Impact factor: 7.723
Authors: Laura Antonucci; Gabriele Canciani; Angela Mastronuzzi; Andrea Carai; Giada Del Baldo; Francesca Del Bufalo Journal: Front Immunol Date: 2022-05-04 Impact factor: 8.786
Authors: Amirhossein Mardi; Anastasia V Shirokova; Rebar N Mohammed; Ali Keshavarz; Angelina O Zekiy; Lakshmi Thangavelu; Talar Ahmad Merza Mohamad; Faroogh Marofi; Navid Shomali; Amir Zamani; Morteza Akbari Journal: Cancer Cell Int Date: 2022-04-29 Impact factor: 6.429